About

ACCESS BIO

Access to Life,
Bio for Hope

ACCESS BIO

Access to Life, Bio for Hope

Overview

Because Access is Everything

Even the most sophisticated, cutting-edge medical diagnostics aren’t of value unless we can get them to those who need them most. At Access Bio, we believe every life is precious, and every human on earth deserves the opportunity to live a healthy life, free from the threat of infectious diseases.

Access Bio is dedicated to the prevention and early diagnosis of infectious diseases through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. Based on the greatest needs and the potential to do the most good, we work with partners across the world, including the Bill and Melinda Gates Foundation, the World Health Organization, Doctors Without Borders, UNICEF, and many others.

Vision

Our Vision and Strategy

A Sustainable Business Based on Innovation, Value, and Global Good

Vision

Our Vision and Strategy

A Sustainable Business Based on Innovation, Value, and Global Good

Global pioneer in invitro diagnostic technologies

Promote health and well-being of mankind via accurate diagnosis of diseases

Reinforce market
presence and
diversify markets

Reinforce market footing
in malaria diagnosis;
launch new diagnostic
products including tests
for COVID-19, G6PD
deficiency, dengue fever,
influenza, and strep A

Strengthen quality
control and customer
relationships

Maintain stringent quality
control; strengthen
relationships with customers
including international
agencies, non-profit
organizations, and retailers.

Develop
value-added
products

Build a portfolio of
value-added products
based on cutting-edge
technologies in in vitro
diagnostics.

Enhance
sustainability
of profits

Reduce costs via product
diversification, economies
of scale, and production
automation.

Vision

Our Vision and Strategy

A Sustainable Business Based on Innovation, Value, and Global Good

Global pioneer in invitro diagnostic technologies

Promote health and well-being of mankind via accurate diagnosis of diseases

Reinforce market presence and diversify markets

Reinforce market footing in malaria diagnosis; launch new diagnostic products including tests for COVID-19, G6PD deficiency, dengue fever, influenza, and strep A

Strengthen quality control and customer relationships

Maintain stringent quality control; strengthen relationships with customers including international agencies, non-profit organizations, and retailers.

Develop value-added products

Build a portfolio of value-added products based on cutting-edge technologies in in vitro diagnostics.

Enhance sustainability of profits

Reduce costs via product diversification, economies of scale, and production automation.

CEO MESSAGE

Each and every
life is precious

A healthy life, free of illness, is a long-held wish in society. Guided by the basic principles of cherishing life and health for all people, Access Bio has been dedicated to the research, development and quality improvement of the medical diagnosis industry. Through the development of in vitro diagnostics technology, Access Bio has successfully commercialized products of outstanding quality to battle malaria and other diseases that pose a serious health threat across the globe.

Since our inception in 2002, we have built a strong presence in the global market for the diagnostic testing of malaria and instilled hope for a healthy life among those suffering from this deadly disease.

Quality acknowledged by the WHO

In accordance with the World Health Organization’s global fight against malaria, demand is steadily growing for high-quality rapid diagnostics tests (RDT) for prompt and accurate diagnosis. The superior quality of Access Bio’s CareStart™ has been verified through the malaria diagnostics kit testing by the U.S. Centers for Disease Control and Prevention upon request from the WHO. This has enabled Access Bio to forge partnerships with international agencies including the WHO, UNICEF, Global Fund, and MSF (Medecins Sans Frontieres, Doctors without Borders). Drawing from our solid footing in malaria diagnosis and accumulated R&D expertise, Access Bio strives to develop diagnostic tests in diverse fields and enhance the well-being and quality of life for people around the world.

Our Work Has Just Begun

As we look toward the future, Access Bio will not merely respond to the changing environment, but move forward with a proactive stance.
With efficient processes and a dynamic culture, we will harness our competitive advantage to develop next-generation technologies and sustain growth. As a world leader in medical diagnosis, Access Bio is committed in promoting hope for a healthy life and garnering the trust of all stakeholders.

Thank you.


Young H. Choi – Chairman & CEO

CEO MESSAGE

Each and every
life is precious

A healthy life, free of illness, is a long-held wish in society. Guided by the basic principles of cherishing life and health for all people, Access Bio has been dedicated to the research, development and quality improvement of the medical diagnosis industry. Through the development of in vitro diagnostics technology, Access Bio has successfully commercialized products of outstanding quality to battle malaria and other diseases that pose a serious health threat across the globe.

Since our inception in 2002, we have built a strong presence in the global market for the diagnostic testing of malaria and instilled hope for a healthy life among those suffering from this deadly disease.

Quality acknowledged by the WHO

In accordance with the World Health Organization’s global fight against malaria, demand is steadily growing for high-quality rapid diagnostics tests (RDT) for prompt and accurate diagnosis. The superior quality of Access Bio’s CareStart™has been verified through the malaria diagnostics kit testing by the U.S. Centers for Disease Control and Prevention upon request from the WHO. This has enabled Access Bio to forge partnerships with international agencies including the WHO, UNICEF, Global Fund, and MSF (Medecins Sans Frontieres, Doctors without Borders). Drawing from our solid footing in malaria diagnosis and accumulated R&D expertise, Access Bio strives to develop diagnostic tests in diverse fields and enhance the wellbeing and quality of life for people around the world.

Our Work Has Just Begun

As we look toward the future, Access Bio will not merely respond to the changing environment, but move forward with a proactive stance.

With efficient processes and a dynamic culture, we will harness our competitive advantage to develop next-generation technologies and sustain growth. As a world leader in medical diagnosis, Access Bio is committed in promoting hope for a healthy life and garnering the trust of all stakeholders.

Thank you.


Young H. Choi – Chairman & CEO

Access Bio News

Stay Up to Date with
Access Bio News
and
Events

Read about our new product releases and events, and learn more about how Access Bio products are helping to fight disease all over the world.
Learn more

Access Bio News

Stay Up to Date with Access Bio News and Events

Read about our new product releases and events, and learn more about how Access Bio products are helping to fight disease all over the world.
Learn more

NEWS

Getting Tests Where They’re Needed Most

Learn more
July 12, 2020

PRODUCTS

The Newest Asset in the Fight Against COVID-19

Learn more
July 15, 2020

Knowledge

The Goal: Ending Malaria in Our Lifetime

Learn more
June 20, 2020

SCIENCE

The Scientists Who are Making a Difference

JULY 08, 2020

Getting Tests Where They’re Needed Most

Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.

Core to fulfilling this mission is Access Bio’s unique structure that allows them to be both nimble and responsive to emerging threats and trends but gives them the size, strength, and reach necessary to distribute fairly-priced products all over the world. Access Bio is headquartered in the United States, with production facilities strategically located in New Jersey, Ethiopia, and South Korea. Access Bio can produce more than 170 million rapid diagnostic tests a year, and distributes products to more than 120 different countries.

At the beginning of COVID-19 pandemic, Access Bio mobilized to produce the high-quality, highly sensitive tests required to help stop the spread. It has developed PCR, antigen, and antibody testing, to better assess not only active infections but past exposure to SARS-CoV-2. Access Bio quickly received approval to distribute the products throughout Asia, and, in March 2020, Access Bio’s PCR test was CE-marked. On July 21, 2020, the company announced that its CareStart™ COVID-19 MDx RT-PCR test was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration.

The announcement comes at a critical time: the nation lost valuable time in developing effective testing options and had been burdened by sub-standard or defective tests. Access Bio has long been a trusted partner to organizations that include UNICEF and the World Health Organization. Together with the fact that the company can domestically produce more than 1.2 million tests a day, there is reason for hope that the nation may be able to test at the volume necessary to aid containment efforts.

The Goal: Ending Malaria in Our Lifetime

Malaria and its effects are primarily concentrated in poor, developing nations. in 2018, there were an estimated 228 million cases around the world and more than 400,000 deaths. Of those, more than 90% of cases and mortalities occurred in the sub-Saharan region of Africa, and children under the age of 5 account for two-thirds of all malaria deaths worldwide. This is a disease that robs nations not only of lives but hope for a better future.

The good news is that we have the tools to fight this deadly disease, and experts agree that if these concentrated efforts are sustained, we can eradicate malaria by 2050. The impressive efforts are coordinated by a series of public/private and non-profit partnerships, including organizations such as UNICEF, the World Health Organization, the Bill and Melinda Gates Foundation, GE, and the Global Good Fund, among many others.

Wide-spread testing and surveillance are critical components in the fight against malaria. Over the years, testing has advanced significantly, and today’s tests are characterized by their:

Access Bio has developed and commercialized a range of malaria testing products, including both RDT and serology tests, allowing health officials to determine if a population has recently been exposed to the malaria parasite, which, in turn, enables the rapid actions necessary to quell or even prevent outbreaks.

The global company, with headquarters in the United States, has received significant grants from the Bill and Melinda Gates Foundation and the Global Good Fund to continue its innovative work – not only in the development of high-quality testing tools, but in producing them at the necessary scale.

“With our commercialization experience and mass production facilities, Access Bio will be able to fully accommodate the commercialization of the highly sensitive RDTs at affordable prices. These tests will be the next generation of diagnostic testing and a big step towards the eradication of malaria,” said Young Ho Choi, Chief Executive Officer of Access Bio.

Access Bio Granted Emergency Use Authorization by FDA for CareStart™ COVID-19 MDx RT-PCR Test

Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Molecular Test that May Provide Laboratories Results in 83 Minutes or Less

July 21, 2020 (SOMERSET, NJ) -- Access Bio, Inc., a long-standing leader in the development of diagnostic tests for infectious diseases through research, development and manufacturing, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Emergency Use Authorization (EUA) for its SARS CoV-2 RT-PCR test.

Manufactured entirely in the United States, the CareStart™ COVID-19 MDx RT-PCR test uses real-time reverse transcription-polymerase chain reaction (RT-PCR) to detect RNA of the COVID-19 nucleocapsid gene (N gene) and RNA-dependent RNA polymerase gene (RdRp gene) in test subjects, resulting in faster results (83 minutes), as well as 100% sensitivity and 100% specificity.

Access Bio has confirmed 100% consistency in positive (PPA) and negative (NPA) groups during clinical evaluations from samples collected by nasopharyngeal swab from symptomatic patients during the 2020 COVID-19 pandemic period. The CareStart™ COVID-19 MDx RT-PCR test is authorized for distribution and use by healthcare professionals and health systems conducting COVID-19 testing. Specimens are then delivered for analysis to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) who are subject to reporting test results to healthcare providers and relevant public health authorities as appropriate. Analysis does not require a proprietary system and can be run on some of the most common PCR processing solutions, such as Bio-Rad’s CFX96 Dx system and Thermo Fisher Scientific’s Applied Biosystems 7500 or 7500 Fast RT-PCR instrument. Additional information surrounding instructions for use with each system can be found at https://carestart.com/.

“The novel coronavirus is showing no sign of slowing in the United States or other parts of the world, making the ability to quickly scale testing and diagnosis a priority,” said Young H. Choi, President and CEO, Access Bio. “Our products are manufactured wholly in the United States and are used by the world's largest global health and humanitarian response organizations. We’ve worked to ensure the CareStart’s accuracy and reliability will make it a leading diagnostic testing solution in a market plagued by false methodologies and subpar alternatives.”

The CareStart™ COVID-19 MDx RT-PCR test is designed for use on SARS-CoV-2 nucleic acid that has been extracted, isolated and purified from nasopharyngeal or oropharyngeal swab specimens. The purified nucleic acid is then reverse transcribed into cDNA followed by PCR amplification and detection using an authorized realtime (RT) PCR instrument. The CareStart™ COVID-19 MDx RT-PCR test includes: 4x1 Step RT-PCR Mix, SARS-CoV-2 primer/probe Mix, MS2 Phage Control, External Positive Control, and External Negative Control.

Access Bio’s CareStart™ RT-PCR test is the first in the company’s CareStart line to be granted Emergency Use Authorization by the FDA, with an IgM/IgG antibody kit also currently under evaluation for FDA EUA. Upon receiving validation, the CareStart™ COVID-19 IgM/IgG Rapid Diagnostic Test will be distributed in partnership with Intrivo Diagnostics, which will act as a resource for qualified buyers -- providers & healthcare professionals, payers and patients -- to purchase the point-of-care antibody kits.

“The availability of the CareStart™ COVID-19 MDx RT-PCR brings needed Covid-19 viral diagnostic testing to millions of patients across the U.S. and world during the current pandemic,” said Michael Harbour, MD, MPH, Chief Medical Officer, Intrivo Diagnostics. “These high-quality tests are manufactured in the U.S. by Access Bio, a company with a long history of engineering and manufacturing superior quality diagnostic kits for malaria, dengue, typhus and other infectious diseases."

Established in 2002, Access Bio has a proven track record of releasing top-performing products, including its CareStart™ Malaria Rapid Diagnostic Test (RDT), which is global leader in malaria testing market, supplying more that 100 million malaria tests per year. The product’s success garnered the New Jersey-based manufacturer recognition from the World Health Organization (WHO) and earned numerous accolades and research grants. Access Bio went on to land R&D partnerships with the several US GOV organizations.

Access Bio distributes its products to more than 120 countries around the world, thanks to scalable infrastructure consisting of R&D and production facilities in the United States, South Korea and Ethiopia. Access Bio is traded on the Korean Stock Exchange (KRX) under the stock symbol, KR: 950130.

For more information about Access Bio and the CareStart™ COVID-19 MDx RT-PCR test, please visit: https://www.carestart.com.

About Access Bio:

Access Bio was founded by Young Ho Choi in 2002 and quickly established itself as a long-standing global leader in diagnostic testing, striving to create a foundation of well-being for all people. Access Bio’s molecular technologies diagnose infection and disorders using genetic information, such as DNA and RNA to obtain more accurate diagnoses compared to conventional immunological or biochemical diagnostic products. With a history of creating revolutionary products, such as the CareStart™ Malaria Rapid Detection Test, Access Bio remains a leader in accurate, sustainable and cost-effect diagnosis solutions.

About Intrivo Diagnostics:

Headquartered in Los Angeles, CA, Intrivo Diagnostics is an organization driven by science and dedicated to providing sophisticated and accurate diagnostic testing to save lives and slow the spread of infectious diseases.  Intrivo Diagnostics’ mission is to distribute exceptional products to address the urgent demand for high-quality diagnostic testing. In keeping with that mission, Intrivo Diagnostic is the exclusive distribution partner for Access Bio, Inc.’s CareStart™ line of COVID-19 testing products, all of which are solely manufactured in the USA.

Getting Tests Where They’re Needed Most

Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.

Core to fulfilling this mission is Access Bio’s unique structure that allows them to be both nimble and responsive to emerging threats and trends but gives them the size, strength, and reach necessary to distribute fairly-priced products all over the world. Access Bio is headquartered in the United States, with production facilities strategically located in New Jersey, Ethiopia, and South Korea. Access Bio can produce more than 170 million rapid diagnostic tests a year, and distributes products to more than 120 different countries.

At the beginning of COVID-19 pandemic, Access Bio mobilized to produce the high-quality, highly sensitive tests required to help stop the spread. It has developed PCR, antigen, and antibody testing, to better assess not only active infections but past exposure to SARS-CoV-2. Access Bio quickly received approval to distribute the products throughout Asia, and, in March 2020, Access Bio’s PCR test was CE-marked. On July 21, 2020, the company announced that its CareStart™ COVID-19 MDx RT-PCR test was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration.

The announcement comes at a critical time: the nation lost valuable time in developing effective testing options and had been burdened by sub-standard or defective tests. Access Bio has long been a trusted partner to organizations that include UNICEF and the World Health Organization. Together with the fact that the company can domestically produce more than 1.2 million tests a day, there is reason for hope that the nation may be able to test at the volume necessary to aid containment efforts.

Access Bio Granted Emergency Use Authorization by FDA for CareStart™ COVID-19 MDx RT-PCR Test

Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Molecular Test that May Provide Laboratories Results in 83 Minutes or Less

July 21, 2020 (SOMERSET, NJ) -- Access Bio, Inc., a long-standing leader in the development of diagnostic tests for infectious diseases through research, development and manufacturing, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Emergency Use Authorization (EUA) for its SARS CoV-2 RT-PCR test.

Manufactured entirely in the United States, the CareStart™ COVID-19 MDx RT-PCR test uses real-time reverse transcription-polymerase chain reaction (RT-PCR) to detect RNA of the COVID-19 nucleocapsid gene (N gene) and RNA-dependent RNA polymerase gene (RdRp gene) in test subjects, resulting in faster results (83 minutes), as well as 100% sensitivity and 100% specificity.

Access Bio has confirmed 100% consistency in positive (PPA) and negative (NPA) groups during clinical evaluations from samples collected by nasopharyngeal swab from symptomatic patients during the 2020 COVID-19 pandemic period. The CareStart™ COVID-19 MDx RT-PCR test is authorized for distribution and use by healthcare professionals and health systems conducting COVID-19 testing. Specimens are then delivered for analysis to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) who are subject to reporting test results to healthcare providers and relevant public health authorities as appropriate. Analysis does not require a proprietary system and can be run on some of the most common PCR processing solutions, such as Bio-Rad’s CFX96 Dx system and Thermo Fisher Scientific’s Applied Biosystems 7500 or 7500 Fast RT-PCR instrument. Additional information surrounding instructions for use with each system can be found at https://carestart.com/.

“The novel coronavirus is showing no sign of slowing in the United States or other parts of the world, making the ability to quickly scale testing and diagnosis a priority,” said Young H. Choi, President and CEO, Access Bio. “Our products are manufactured wholly in the United States and are used by the world's largest global health and humanitarian response organizations. We’ve worked to ensure the CareStart’s accuracy and reliability will make it a leading diagnostic testing solution in a market plagued by false methodologies and subpar alternatives.”

The CareStart™ COVID-19 MDx RT-PCR test is designed for use on SARS-CoV-2 nucleic acid that has been extracted, isolated and purified from nasopharyngeal or oropharyngeal swab specimens. The purified nucleic acid is then reverse transcribed into cDNA followed by PCR amplification and detection using an authorized realtime (RT) PCR instrument. The CareStart™ COVID-19 MDx RT-PCR test includes: 4x1 Step RT-PCR Mix, SARS-CoV-2 primer/probe Mix, MS2 Phage Control, External Positive Control, and External Negative Control.

Access Bio’s CareStart™ RT-PCR test is the first in the company’s CareStart line to be granted Emergency Use Authorization by the FDA, with an IgM/IgG antibody kit also currently under evaluation for FDA EUA. Upon receiving validation, the CareStart™ COVID-19 IgM/IgG Rapid Diagnostic Test will be distributed in partnership with Intrivo Diagnostics, which will act as a resource for qualified buyers -- providers & healthcare professionals, payers and patients -- to purchase the point-of-care antibody kits.

“The availability of the CareStart™ COVID-19 MDx RT-PCR brings needed Covid-19 viral diagnostic testing to millions of patients across the U.S. and world during the current pandemic,” said Michael Harbour, MD, MPH, Chief Medical Officer, Intrivo Diagnostics. “These high-quality tests are manufactured in the U.S. by Access Bio, a company with a long history of engineering and manufacturing superior quality diagnostic kits for malaria, dengue, typhus and other infectious diseases."

Established in 2002, Access Bio has a proven track record of releasing top-performing products, including its CareStart™ Malaria Rapid Diagnostic Test (RDT), which is global leader in malaria testing market, supplying more that 100 million malaria tests per year. The product’s success garnered the New Jersey-based manufacturer recognition from the World Health Organization (WHO) and earned numerous accolades and research grants. Access Bio went on to land R&D partnerships with the several US GOV organizations.

Access Bio distributes its products to more than 120 countries around the world, thanks to scalable infrastructure consisting of R&D and production facilities in the United States, South Korea and Ethiopia. Access Bio is traded on the Korean Stock Exchange (KRX) under the stock symbol, KR: 950130.

For more information about Access Bio and the CareStart™ COVID-19 MDx RT-PCR test, please visit: https://www.carestart.com.

About Access Bio:

Access Bio was founded by Young Ho Choi in 2002 and quickly established itself as a long-standing global leader in diagnostic testing, striving to create a foundation of well-being for all people. Access Bio’s molecular technologies diagnose infection and disorders using genetic information, such as DNA and RNA to obtain more accurate diagnoses compared to conventional immunological or biochemical diagnostic products. With a history of creating revolutionary products, such as the CareStart™ Malaria Rapid Detection Test, Access Bio remains a leader in accurate, sustainable and cost-effect diagnosis solutions.

About Intrivo Diagnostics:

Headquartered in Los Angeles, CA, Intrivo Diagnostics is an organization driven by science and dedicated to providing sophisticated and accurate diagnostic testing to save lives and slow the spread of infectious diseases.  Intrivo Diagnostics’ mission is to distribute exceptional products to address the urgent demand for high-quality diagnostic testing. In keeping with that mission, Intrivo Diagnostic is the exclusive distribution partner for Access Bio, Inc.’s CareStart™ line of COVID-19 testing products, all of which are solely manufactured in the USA.

The Goal: Ending Malaria in Our Lifetime

Malaria and its effects are primarily concentrated in poor, developing nations. in 2018, there were an estimated 228 million cases around the world and more than 400,000 deaths. Of those, more than 90% of cases and mortalities occurred in the sub-Saharan region of Africa, and children under the age of 5 account for two-thirds of all malaria deaths worldwide. This is a disease that robs nations not only of lives but hope for a better future.

The good news is that we have the tools to fight this deadly disease, and experts agree that if these concentrated efforts are sustained, we can eradicate malaria by 2050. The impressive efforts are coordinated by a series of public/private and non-profit partnerships, including organizations such as UNICEF, the World Health Organization, the Bill and Melinda Gates Foundation, GE, and the Global Good Fund, among many others.

Wide-spread testing and surveillance are critical components in the fight against malaria. Over the years, testing has advanced significantly, and today’s tests are characterized by their:

Access Bio has developed and commercialized a range of malaria testing products, including both RDT and serology tests, allowing health officials to determine if a population has recently been exposed to the malaria parasite, which, in turn, enables the rapid actions necessary to quell or even prevent outbreaks.

The global company, with headquarters in the United States, has received significant grants from the Bill and Melinda Gates Foundation and the Global Good Fund to continue its innovative work – not only in the development of high-quality testing tools, but in producing them at the necessary scale.

“With our commercialization experience and mass production facilities, Access Bio will be able to fully accommodate the commercialization of the highly sensitive RDTs at affordable prices. These tests will be the next generation of diagnostic testing and a big step towards the eradication of malaria,” said Young Ho Choi, Chief Executive Officer of Access Bio.